文献速递前列腺癌

转移性去势抵抗性前列腺癌的新型免疫衔接器与细胞疗法:BiTE、BiKE、TriKE与CAR

Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-05-25

本综述聚焦转移性去势抵抗性前列腺癌(mCRPC)免疫治疗进展,指出检查点抑制剂和现有细胞产品疗效有限,与前列腺癌免疫冷微环境相关。

要点

  • mCRPC免疫冷微环境限制检查点抑制剂和现有细胞疗法疗效。
  • 多种免疫衔接器和细胞疗法在研,显示改善mCRPC结局的潜力。

核心结论

  • 多种免疫衔接器和细胞疗法处于研发管线中,展示出解决mCRPC患者更好结局障碍的潜力。

研究设计与样本

  • 综述,检索PubMed和ClinicalTrials.gov数据库中的活跃临床试验。

主要发现

  • 已发表数据按治疗类别汇编和呈现。

关键数值与推荐

  • 检索词包括「bispecific T-cell engager」「bispecific killer engager」「trispecific killer engager」「chimeric antigen receptor」「metastatic castration-resistant prostate cancer」「neuroendocrine prostate cancer」。

临床怎么用

  • 为mCRPC患者考虑免疫衔接器和细胞疗法临床试验提供参考。

局限性

  • 综述基于已发表数据和活跃临床试验,未报告原始研究样本量或疗效数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Checkpoint inhibitors and currently approved cellular products for metastatic castration-resistant prostate cancer have not resulted in revolutionary changes in outcomes compared to other solid tumors. Much of this lack of progress is attributed to the unique tumor microenvironment of prostate cancer that is often immunologically cold and immunosuppressive. These unique conditions emphasize the need for novel therapeutic options. In this review, we will discuss progress made in design of T- and NK cell immune engagers in addition to chimeric antigen receptor products specifically designed for prostate cancer that are currently under investigation in clinical trials. METHODS: We searched peer-reviewed literature on the PubMed and the ClinicalTrials.gov databases for active clinical trials using the terms "bispecific T-cell engager," "bispecific killer engager," "trispecific killer engager," "chimeric antigen receptor," "metastatic castration-resistant prostate cancer," and "neuroendocrine prostate cancer." RESULTS: Ten bispecific T-cell engager studies and nine chimeric antigen receptor-based products were found. Published data were compiled and presented based on therapeutic class. CONCLUSIONS: Multiple immune engagers and cell therapies are in the development pipeline and demonstrate promise to address barriers to better outcomes for metastatic castration-resistant prostate cancer patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Zorko NA, Ryan CJ. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs? Prostate Cancer Prostatic Dis. 2021. PMID: 34035459. doi:10.1038/s41391-021-00381-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。